Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

A was non-inferior to RISPERDAL CONSTA in the treatment of schizophrenia in this trial, which validates that these are both good options," said George Simpson, M.D., professor of research at Keck School of Medicine, University of Southern California and clinical investigator for the INVEGA SUSTENNA program. "The differences between the two products, such as the shorter or longer dosing interval or the need for oral supplementation, provide options for physicians to decide what will work best for an individual patient."

About the Study

The 13-week, randomized, double-blind, double-dummy trial included 1220 adults with a diagnosis of schizophrenia and a PANSS total score of 60 to 120. Participants were randomly assigned to receive INVEGA SUSTENNA (IS) plus oral placebo or RISPERDAL CONSTA (RC) plus oral risperidone for the first three weeks.

Patients assigned to IS received an initiation dosing regimen of 234* mg on day 1 and 156 mg on day 8, followed by once-monthly dosing on day 36 (78 mg or 156 mg) and day 64 (78 mg, 156 mg, or 234 mg). Additional placebo injections were administered to match RC dosing. Patients assigned to RC received their first injection on day 8, followed by biweekly injections on day 22, 36, 50, 64 and 78. This was supplemented with placebo injections to match IS dosing. The 25 mg starting dose of RC could have been increased up to 37.5 mg starting on day 36 and up to 50 mg on day 64. Patients on RC received mandatory oral risperidone supplementation from days 1 to 28. Oral supplementation was optional with subsequent dose increases.

The primary endpoint of the trial was the change in the PANSS total score versus baseline. Non-inferiority would be concluded by calculation using a 95% confidence interval (CI) based on a pre-specified change in total PANSS score. Secondary efficacy measures included change from baseline for Clinical Global Impression-Severity (CGI-S) and Personal and Social Pe
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... 7 Ardea,Biosciences, Inc. (Nasdaq: RDEA ) ... activity of the Company,s non-nucleoside reverse,transcriptase inhibitor (NNRTI) ... known causative agent of AIDS,including NNRTI-resistant strains., ... Conference on Retroviruses,and Opportunistic Infections (CROI) in Boston., ...
... gastrointestinal and lipid effects between ... N.J., Feb. 6 Bristol-Myers Squibb,Company (NYSE: ... study, in which,300 mg of once-daily REYATAZ(R) (atazanavir ... similar antiviral efficacy to twice-daily,lopinavir 400 mg and ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... Thermage, Inc.,(Nasdaq: THRM ), announced today that ... and full year ended December 31, 2007, after the,market ... also host a,conference call and webcast on Tuesday, February ... to discuss the financial results and,current corporate developments. The ...
... The Bishop of Manchester,has made a series of serious ... researcher, inventor of the science of,Plastination, and creator of ... and at a Press Conference at Manchester Cathedral on ... WORLDS 4,exhibition, to be hosted by the Museum of ...
... It,s one thing to daydream about all,the free time ... to,seriously map out the steps you need to take ... Listen to this report from AXA Equitable (NYSE: ... access video, audio, text, graphics and,photos for free and ...
... study, a new technique helped patients retrieve long-lost details ... interviewing technique has drawn out extensive details hidden in ... researchers say. , There,s ongoing debate about whether long-term ... the medial temporal lobe, which contains the memory-processing center ...
... Record Annual Net Sales and Net Income, SALT LAKE ... a leading producer of advanced digital hearing aids,today announced results ... 2007 of $32.3 million were up 12.4% over the $28.7 ... year 2007 of $122.5,million improved 16.1% over the $105.5 million ...
... of $55.9 Million and Contract Value ... Growth of ... WASHINGTON, Feb. 5 The Advisory Board Company,(Nasdaq: ABCO ) ... March 31, 2008. Revenue for the quarter increased,15% to $55.9 million, from ...
Cached Medicine News:Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 2Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 3Health News:The Institute for Plastination Responds to the Bishop of Manchester's Media Blitz, Assertions, and Allegations About BODY WORLDS Anatomical Exhibition Coming to Manchester 4Health News:Brain Injury May Not Erase Long-Term Memory 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 2Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 3Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 4Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 5Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 6Health News:Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007 7Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 2Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 3Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 4Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 5Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 6Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 7Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 8Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 9Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 10Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 11Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 12Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 13Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 14Health News:The Advisory Board Company Reports Fiscal Year 2008 Third Quarter Results 15
Inquire...
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: